Glucose Monitoring & CGM, Explained: The 2026 Field Guide
What glucose monitoring & cgm covers, why it matters in 2026, and the numbers decision-makers should know.
Few corners of healthcare technology are moving faster than glucose monitoring & cgm. Continuous glucose monitoring for diabetes and the OTC metabolic wave. This explainer sets out what the category actually covers, why it has moved to the center of wearables & rpm strategy, and the numbers every decision-maker should have at hand.
What it covers
Continuous glucose monitoring for diabetes and the OTC metabolic wave. In practice, that spans the vendors building the technology, the health systems and payers deploying it, and the regulators writing the rules around it. The category sits inside our broader Wearables & RPM coverage, and its daily developments stream into the live Glucose Monitoring & CGM feed.
Why it matters in 2026
Consider the current numbers: dexcom won authorization for a 15.5-day CGM sensor with 8.0% MARD accuracy (our coverage).
Meanwhile, global wearable shipments now exceed 136.5 million units per quarter.
Meanwhile, oura has sold 5.5 million rings, projects roughly $1.5 billion in 2026 revenue, and has filed confidentially for an IPO (our coverage).
What to watch next
Three signals will tell you where glucose monitoring & cgm goes from here: the reimbursement decisions now moving through CMS and commercial payers, the consolidation pattern as larger platforms absorb point solutions, and the evidence base - peer-reviewed results increasingly separate durable categories from demo-ware.
The bottom line
The organizations that win here will be the ones that treat this as an operating discipline, not a procurement exercise. For the latest developments, follow our continuously updated Glucose Monitoring & CGM topic page.